Top Stories

Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports

Published by Uma Rajagopal

Posted on September 23, 2024

1 min read

· Last updated: January 29, 2026

Add as preferred source on Google
Novo Nordisk CEO preparing for congressional hearing on drug prices - Global Banking & Finance Review
Featured image depicts Novo Nordisk's CEO ahead of a congressional hearing regarding the pricing of weight loss drugs like Ozempic, amidst government scrutiny - Global Banking & Finance Review.
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) – Novo Nordisk’s chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday. (Reporting by Disha Mishra in Bengaluru; Editing […]

(Reuters) – Novo Nordisk’s chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.

(Reporting by Disha Mishra in Bengaluru; Editing by Christopher Cushing)

Frequently Asked Questions

What is a blockbuster drug?
A blockbuster drug is a pharmaceutical product that generates annual sales of over $1 billion. These drugs are often widely prescribed and have significant market impact.
What is a congressional hearing?
A congressional hearing is a formal meeting held by a legislative body to gather information, discuss issues, and hold inquiries. It often involves testimonies from experts and stakeholders.

Tags

Related Articles

More from Top Stories

Explore more articles in the Top Stories category